Experimental assessment of photodynamic therapy with chlorins for malignant mesothelioma.

OBJECTIVE Photodynamic therapy (PDT) with two chlorin sensitisers was assessed on nude mice bearing human mesothelioma xenografts, and on intrathoracic tissues of minipigs with the same drug-light conditions to optimise the antitumour activity of PDT while preventing photosensitising injury to normal tissues. METHODS Laser light (20 J/cm2) at 652 nm was delivered to the xenografts 1-4 days after i.p. administration of 0.1 mg/kg m-tetrahydroxyphenyl-chlorin (mTHPC) or an equimolar dose of polyethylene glycol-derived mTHPC (pegylated mTHPC), respectively. The extent of tumour necrosis was assessed by histomorphometry. Intraoperative PDT was then performed to the thoracic cavity of minipigs through a sternotomy with the same drug-light conditions at drug-light intervals ranging from 12 h to 6 days after i.v. administration of mTHPC and pegylated mTHPC, respectively. RESULTS Both, mTHPC and pegylated mTHPC, resulted in photosensitised necrosis of mesothelioma xenografts at drug-light intervals from 1 to 4 days but the extent of necrosis was significantly larger by use of pegylated mTHPC instead of mTHPC at a drug-light interval of 3 and 4 days. The optimal tumourcidal effect was achieved with pegylated mTHPC at a drug-light interval of 4 days. The photosensitising effect of mTHPC on intrathoracic tissues of minipigs revealed severe damage of virtually all tissues except nerves at short drug-light intervals. Tissue damage gradually became less at longer drug-light intervals and was absent at intervals of 3 days and longer. In contrast, pegylated mTHPC resulted in no obvious change to any structure at any drug-light interval assessed. CONCLUSIONS PDT with pegylated mTHPC reveals the potential of selective tumour destruction in this experimental setting and deserves further evaluation for intraoperative application in patients with malignant mesothelioma.

[1]  T. Foster,et al.  Effects of photodynamic therapy on xenografts of human mesothelioma and rat mammary carcinoma in nude mice. , 1994, British Journal of Cancer.

[2]  L. Faber Surgical treatment of asbestos-related disease of the chest. , 1988, The Surgical clinics of North America.

[3]  S. Keller,et al.  Intrathoracic organ injury associated with photodynamic therapy , 1992 .

[4]  T J Dougherty,et al.  Operation and intracavitary photodynamic therapy for malignant pleural mesothelioma: a phase II study. , 1994, The Annals of thoracic surgery.

[5]  V. Rusch,et al.  The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. , 1991, The Journal of thoracic and cardiovascular surgery.

[6]  H. Altermatt,et al.  Photodynamic therapy with m‐tetrahydroxyphenylchlorin in vivo: Optimization of the therapeutic index , 1993, International journal of cancer.

[7]  M. C. Berenbaum,et al.  Photodynamic therapy with chlorins for diffuse malignant mesothelioma: initial clinical results. , 1991, British journal of cancer.

[8]  U Althaus,et al.  Effect of drug‐light interval on photodynamic therapy with meta‐tetrahydroxyphenylchlorin in malignant mesothelioma , 1993, International journal of cancer.

[9]  N L Burnham,et al.  Polymers for delivering peptides and proteins. , 1994, American journal of hospital pharmacy.

[10]  R. Ginsberg,et al.  Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Ash,et al.  New drugs and future developments in photodynamic therapy. , 1993, European journal of cancer.

[12]  H. Pass,et al.  Intrathoracic photodynamic therapy: A canine normal tissue tolerance study and early clinical experience , 1994, Lasers in surgery and medicine.

[13]  G. Bock,et al.  Photosensitizing compounds : their chemistry, biology and clinical use , 1989 .

[14]  J. Taubenberger,et al.  Tolerance of small bowel anastomoses in rabbits to photodynamic therapy with dihematoporphyrin ethers and 630 nm red light , 1993, Lasers in surgery and medicine.

[15]  D. Sugarbaker,et al.  Patterns of failure after trimodality therapy for malignant pleural mesothelioma. , 1997, The Annals of thoracic surgery.

[16]  F. Stewart,et al.  Functional and histological bladder damage in mice after photodynamic therapy: the influence of sensitiser dose and time of administration. , 1993, British Journal of Cancer.

[17]  B. Steinberg,et al.  Photodynamic therapy using m-tetra(hydroxyphenyl) chlorin. An animal model. , 1994, Archives of otolaryngology--head & neck surgery.

[18]  R. Feins,et al.  Photodynamic therapy for human malignant mesothelioma in the nude mouse. , 1990, The Journal of surgical research.

[19]  R. Veenhuizen,et al.  Intraperitoneal photodynamic therapy in the rat: Comparison of toxicity profiles for photofrin and mTHPC , 1994, International journal of cancer.

[20]  M C Berenbaum,et al.  In vivo biological activity of the components of haematoporphyrin derivative. , 1982, British Journal of Cancer.

[21]  H. Oppelaar,et al.  Photosensitizing efficacy of MTHPC‐PDT compared to Photofrin‐PDT in the RIF1 mouse tumour and normal skin , 2006, International journal of cancer.

[22]  J Moan,et al.  Evaluation of a new photosensitizer, meso‐tetra‐hydroxyphenyl‐chlorin, for use in photodynamic therapy: A comparison of its photobiological properties with those of two other photosensitizers , 1994, International journal of cancer.